What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to inform investors that Bristol-Myers Squibb has extended the expiration date for its offers to exchange Celgene Corporation's notes for new notes and cash, and for its solicitation of consents to amend the terms of those Celgene notes. This is a procedural step related to the ongoing acquisition of Celgene.

What are the implications of these exchange offers and consent solicitations for existing Celgene noteholders?

For Celgene noteholders, these offers present an opportunity to exchange their existing notes for new notes issued by Bristol-Myers Squibb, along with some cash. The consent solicitations seek their approval to modify certain terms in the Celgene notes, potentially making them more attractive to BMY or simplifying the post-acquisition debt structure. The success of these offers is tied to the completion of the Celgene acquisition.

When is the Bristol-Myers Squibb acquisition of Celgene expected to close?

The filing indicates that the closing of the merger between Bristol-Myers Squibb and Celgene is expected to occur by the end of 2019. However, the potential for further extensions of the exchange offer and consent solicitation deadlines suggests that the closing date is subject to change.

BRISTOL MYERS SQUIBB CO 8-K SEC Disclosure

Q: Why is Bristol-Myers Squibb extending the exchange offer and consent solicitation deadline?

The extension is primarily to align with the expected timeline for the closing of Bristol-Myers Squibb's acquisition of Celgene. The exchange offers and consent solicitations are conditioned on the merger closing, and if the merger's closing date is delayed, BMY may need to extend the offer expiration date further.

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K on November 1, 2019, to announce an extension of the expiration date for its exchange offers and consent solicitations related to Celgene Corporation notes. The company extended the deadline from November 4, 2019, to November 6, 2019, for its offers to exchange Celgene notes for new BMY notes and cash, as well as to solicit consents for amendments to the Celgene note indentures. These actions are directly linked to Bristol-Myers Squibb's planned acquisition of Celgene, which is anticipated to close by the end of 2019. The exchange offers and consent solicitations are contingent upon the successful closing of the merger. Investors should note that the expiration date may be further extended if the merger closing is delayed. The settlement of these offers is expected to occur shortly after the expiration date and on or about the merger's closing date.

Key Highlights

1BMY extended the expiration date for its exchange offers and consent solicitations concerning Celgene notes.
2The new expiration date is November 6, 2019, an extension from November 4, 2019.
3These offers are a key component of BMY's planned acquisition of Celgene.
4The exchange offers involve trading Celgene notes for new BMY notes and cash.
5The consent solicitations aim to amend restrictive covenants and default provisions in Celgene's existing notes.
6The settlement of these offers is contingent on the closing of the Celgene merger.
7The merger is expected to close by the end of 2019, but further extensions of the offer expiration date are possible.

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Nov 1, 2019)

Summary

Key Highlights

Frequently Asked Questions